Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Critical Care Medicine

• Publication date

  2002-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00003246-200202000-00013PMID 11889306
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prophylactic indomethacin: factors determining permanent ductus arteriosus closure.

  2000cited by this paper
• Reopening of the ductus arteriosus after closure with indomethacin: importance of sustained effective indomethacin serum concentrations.

  1996cited by this paper
• Factors determining reopening of the ductus arteriosus after successful clinical closure with indomethacin.

  1995cited by this paper
• Optimal management of patent ductus arteriosus in the neonate weighing less than 800 g.

  1993cited by this paper
• Indomethacin pharmacokinetics in neonates: the value of volume of distribution as a marker of permanent patent ductus arteriosus closure.

  1991cited by this paper
• Indomethacin for patent ductus arteriosus closure. Application of serum concentrations and pharmacodynamics to improve response.

  1990influential reference
• Indomethacin therapy in premature infants with patent ductus arteriosus--determination of therapeutic plasma levels.

  1989cited by this paper
• High-performance liquid chromatographic determination of indomethacin serum concentrations.

  1988cited by this paper
• Response of the patent ductus arteriosus to indomethacin treatment.

  1987cited by this paper
• Response of the patent ductus arteriosus to indomethacin treatment.

  1987cited by this paper
• Indomethacin therapy in infants with advanced postnatal age and patent ductus arteriosus.

  1986cited by this paper
• Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study.

  1983influential reference
• Furosemide promotes patent ductus arteriosus in premature infants with the respiratory-distress syndrome.

  1983cited by this paper
• Factors determining the loss of ductus arteriosus responsiveness to prostaglandin E.

  1983cited by this paper
• Furosemide prevents the renal side effects of indomethacin therapy in premature infants with patent ductus arteriosus.

  1982cited by this paper
• Pharmacokinetics of indomethacin in the neonate. Relation of plasma indomethacin levels to response of the ductus arteriosus.

  1981cited by this paper
• Understanding the Dose-Effect Relationship

  1981cited by this paper
• Pharmacological closure of ductus arteriosus in preterm infants using indomethacin

  1980cited by this paper
• Plasma indomethacin levels in preterm newborn infants with symptomatic patent ductus arteriosus--clinical and echocardiographic assessments of response.

  1979cited by this paper
• Age-dependent closure of the patent ductus arteriosus by indomethacin.

  1978cited by this paper
• Pharmacologic closure of patent ductus arteriosus in the premature infant.

  1976cited by this paper

• Promising Preventive Strategies for Intraventricular Hemorrhage in Preterm Neonates: A Critical Review

  2025cites this paper
• Factors Predicting Spontaneous Closure of Patent Ductus Arteriosus in Very Low Birth Weight Neonates

  2024cites this paper
• Neonatal acute kidney injury during indomethacin therapy: does it predict ductal closure?

  2023cites this paper
• Effects of prophylactic indomethacin on intraventricular hemorrhage and adverse outcomes in neonatal intensive care unit

  2022cites this paper
• Prophylactic Indomethacin in extremely preterm infants: association with death or BPD and observed early serum creatinine levels

  2021cites this paper
• Incidence, risk and risk factors for acute kidney injury associated with the use of intravenous indomethacin in neonatal patent ductus arteriosus: A 16-year retrospective cohort study

  2021cites this paper
• MANAGEMENT STRATEGIES OF PATENT DUCTUS ARTERIOSUS IN PRETERM INFANTSREVIEW ARTICLE

  2021cites this paper
• Patent Ductus Arteriosus

  2020cites this paper
• Association between changes in urine output and successful indomethacin treatment for patent ductus arteriosus in preterm neonates

  2020cites this paper
• Comparison of Intravenous Paracetamol versus Intravenous Ibuprofen in the Closure of Patent Ductus Arteriosus (PDA) in Preterm Infants

  2020cites this paper
• Role of dopamine and selective dopamine receptor agonists on mouse ductus arteriosus tone and responsiveness

  2019cites this paper
• The Extremely Premature Infant (Micropremie) and Common Neonatal Emergencies

  2019cites this paper
• Molecular docking and pharmacokinetic evaluation of natural compounds as targeted inhibitors against Crz1 protein in Rhizoctonia solani

  2019cites this paper
• Efficacy and complications of oral ibuprofen and intravenous acetaminophen in closure of patent ductus arteriosus of preterm neonates

  2019cites this paper
• Factors associated with non-response to second course indomethacin for PDA treatment in preterm neonates

  2018cites this paper
• Polymorphisms in CYP2C9 are associated with response to indomethacin among neonates with patent ductus arteriosus

  2017cites this paper
• Risk of nonsteroidal anti-inflammatory drug-associated renal dysfunction among neonates diagnosed with patent ductus arteriosus and treated with gentamicin

  2017cites this paper
• Acetaminophen for Patent Ductus Arteriosus in Extremely Low-Birth-Weight Neonates.

  2017cites this paper
• THE EFFECT OF ORAL IBUPROFEN AND ORAL ACETAMINOPHEN IN THE PATENT DUCTUS ARTERIOSUS (PDA) IN PRETERM INFANTS BORN IN KOUVSAR HOSPITAL OF QAZVIN (A COMPARATIVE STUDY)

  2016cites this paper
• Multi-hit hypothesis in kidney development: Drug effects and interactions with extrauterine growth restriction

  2016influential citation
• Metabolism and Drug–Drug Interaction in Pregnant Mother/Placenta/Fetus

  2016cites this paper
• Impact of Early Postnatal NSAID Treatment on Nephrogenesis in Wistar Rats.

  2015cites this paper
• Anesthesia and Ancillary Drugs and the Neonate

  2015cites this paper
• Cardiovascular pediatric critical illness and injury

  2015cites this paper
• Drug-related perinatal damage from the pharmacological point of view

  2014cites this paper
• Effect of NSAIDs and diuretics on nephrogenesis in an ex vivo embryogenic kidney model.

  2013cites this paper
• Effect of Indomethacin Treatment in Full-term Infants with Symptomatic Patent Ductus Arteriosus

  2013cites this paper
• Drug metabolizing enzymes in the perinatal and neonatal period: differences in the expression and activity.

  2013cites this paper
• Clinical Pharmacology of Indomethacin in Preterm Infants: Implications in Patent Ductus Arteriosus Closure

  2013cites this paper
• Paracetamol to induce ductus arteriosus closure: is it valid?

  2013cites this paper
• Chapter 54 – Patent Ductus Arteriosus in the Preterm Infant

  2012cites this paper
• Patent ductus arteriosus in infants <29 weeks gestation — outcomes and factors affecting closure

  2012cites this paper
• Patent Ductus Arteriosus

  2012cites this paper
• Age‐Dependent Expression of Human Drug‐Metabolizing Enzymes

  2012cites this paper
• Systematic review and network meta-analysis of intravenous ibuprofen vs. intravenous indomethacin vs. placebo in the management of clinically and/or echocardiographically important patent ductus arteriosus in preterm infants at greater than 24 hours of life

  2012cites this paper
• Controversies Around Treatment of the Open Duct

  2011cites this paper
• Determinants of surgical repair of patent ductus arteriosus in low-birth-weight infants

  2011cites this paper
• Management of patent ductus arteriosus in term or near-term neonates with respiratory distress.

  2010cites this paper
• Indomethacin Pharmacodynamics Are Altered by Surfactant: A Possible Challenge to Current Indomethacin Dosing Guidelines Created Before Surfactant Availability

  2010cites this paper
• Analysis of outcome in 298 extremely low-birth-weight infants with patent ductus arteriosus.

  2009cites this paper
• Developmental Cardiac Physiology

  2009cites this paper
• Optimum Use of Therapeutic Drug Monitoring and Pharmacokinetics-Pharmacodynamics in the NICU.

  2009cites this paper
• Patent ductus arteriosus: indomethacin, Ibuprofen, surgery, or no treatment at all?

  2009cites this paper
• Furosemide in preterm infants treated with indomethacin for patent ductus arteriosus

  2009cites this paper
• Kinetic Study of the Electrooxidation of Mefenamic Acid and Indomethacin Catalysed on Cobalt Hydroxide Modified Glassy Carbon Electrode

  2009cites this paper
• NSAIDs, prostaglandins and the neonatal kidney

  2009cites this paper
• The ontogeny of drug metabolism enzymes and implications for adverse drug events.

  2008cites this paper
• Increased indomethacin dosing for persistent patent ductus arteriosus in preterm infants: a multicenter, randomized, controlled trial.

  2008cites this paper
• Ibuprofen Lysine for the Prevention and Treatment of Patent Ductus Arteriosus

  2008cites this paper
• A Third Course of Indomethacin

  2008cites this paper
• Continuous infusion versus intermittent bolus doses of indomethacin for patent ductus arteriosus closure in symptomatic preterm infants.

  2008cites this paper
• Orogastric and Intravenous Indomethacin Administration to Very Premature Neonates With Patent Ductus Arteriosus: Population Pharmacokinetics, Absolute Bioavailability, and Treatment Outcome

  2007cites this paper
• The factors associated with the efficacy of indomethacin treatment in premature infants with patent ductus arteriosus

  2007cites this paper
• Pharmacologic, pharmacodynamic, and pharmacokinetic considerations with intravenous Ibuprofen lysine.

  2007cites this paper
• Risk factors for persistent ductus arteriosus patency during indomethacin treatment.

  2007cites this paper
• Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants.

  2007cites this paper
• Indometacina: dosis administrada versus dosis indicada

  2006cites this paper
• Pain control: non-steroidal anti-inflammatory agents.

  2006cites this paper
• Indomethacin decreases furosemide-induced natriuresis and diuresis on the neonatal kidney

  2006cites this paper
• Determination of indomethacin in plasma by micellar electrokinetic chromatography with UV detection for premature infants with patent ducts arteriosus.

  2006cites this paper
• Ontogeny of drug metabolizing enzymes in the neonate.

  2005cites this paper
• High efficacy and minor renal effects of indomethacin treatment during individualized fluid intake in premature infants with patent ductus arteriosus

  2004influential citation
• Indomethacin and renal impairment in neonates

  2004cites this paper
• Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study.

  2004cites this paper
• Neonatal Intensive Care Drug Therapy Update: A Bibliography

  2004cites this paper
• Comparing the efficacy of NSAIDs and paracetamol in children

  2004cites this paper
• Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants.

  2004cites this paper
• Indomethacin Therapy for Patent Ductus Arteriosus in Premature Infants: Efficacy of a Dosing Strategy Based on a Second-Dose Peak Plasma Indomethacin Level and Estimated Plasma Indomethacin Levels

  2004influential citation
• Management of Patent Ductus Arteriosus in Very Preterm Infants in the Post-surfactant Era

  2003cites this paper
• Pharmacological closure of the patent ductus arteriosus

  2003cites this paper
• PATENT DUCTUS ARTERIOSUS (PDA)

  1966cites this paper